Essential Pro Study ( rEPIC04E-HK )
Launched by FUNDACIÓN EPIC · Oct 4, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The Essential Pro Study is a clinical trial aimed at ensuring the safety and effectiveness of a medical device called Essential Pro, which is used to treat conditions like coronary artery disease and ischemic heart disease. This study is being conducted at one center and will involve patients who have already been treated with Essential Pro in a regular hospital setting. It’s important to note that the trial is not yet recruiting participants, but it will include adult patients aged 65 to 74 who can give their informed consent to participate.
If you or a family member are considering participation, you would need to have been treated with Essential Pro and agree to the study by signing a consent form. As a participant, you can expect to provide feedback about your experience with the device, which will help researchers confirm its safety and performance. This study is essential for meeting European medical device regulations, ensuring that the device is both safe and effective for patients who need it.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient treated with Essential Pro according to routine hospital practice and following instructions for use
- • Informed consent signed
- Exclusion Criteria:
- • Not meet inclusion criteria
About Fundación Epic
Fundación Epic is a leading clinical trial sponsor dedicated to advancing medical research and innovation. With a robust focus on improving patient outcomes, the foundation collaborates with healthcare professionals, research institutions, and industry partners to design and implement clinical studies across various therapeutic areas. Fundación Epic emphasizes ethical standards, scientific integrity, and patient safety, ensuring that all trials are conducted with the utmost care and rigor. Through its commitment to fostering cutting-edge research and promoting collaboration, Fundación Epic aims to contribute significantly to the development of new therapies and improve healthcare solutions globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lai Chi Kok, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported